CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery 中国心力衰竭诊断和治疗指南2018 sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

Clinical Trial2020 Aug 18;9(16):e015103.

JOURNAL:J Am Heart Assoc. Article Link

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus

K Ejiri, T Miyoshi, MUSCAT‐HF Study Investigators. Keywords: B‐type natriuretic peptide; DM; HF; sodium‐glucose cotransporter 2 inhibitor

Full Text PDF